Background There are very few options to treat multidrugresistant bacterial infections in children. A major barrier is the duration and complexity of regulatory trials of new antibiotics. Extrapolation of safety data from adult trials could facilitate drug development for children. Objective We performed a systematic review on the safety of antibiotic clinical trials (CTs) in children (0-18 years) to evaluate the overall quality of safety trials conducted in children and to determine if age-specific adverse events (AEs) could be identified for specific antibiotic classes. Data Sources We searched the MEDLINE, Cochrane CENTRAL, and ClinicalTrials.gov electronic databases for trials conducted between 2000 and 2016.
Study Selection All trials in which safety was declared a primary or secondary endpoint were included. Exclusion criteria were (1) topical or inhalational route of administration; (2) non-infectious conditions; (3) administration for prophylaxis rather than treatment; (4) selected population (i.e. cystic fibrosis, malignancies, HIV and tuberculosis); and (5) design other than randomized controlled trials. Trials reporting data on both adults and children were included only if paediatric results were reported separately. Data Extraction and Synthesis Two authors independently extracted the data. To assess the quality of published trials, the Extension for harms for Consolidated Standards of Reporting Trials (CONSORT) Statement 2004 was used. Main Outcome and Measure In order to quantitatively assess the rate of developing AEs by drug class, the numbers of overall and body-system-specific AEs were collected for each study arm, and then calculated per single drug class as median and interquartile range (IQR) of the proportions across CTs. The AEs most frequently reported were compared in the meta-analysis by selecting the CTs on the most represented drug classes. Results Eighty-three CTs were included, accounting for 27,693 children. Overall, 69.7% of CONSORT items were fully reported. The median proportion of children with any AE was 22.5%, but did not exceed 8% in any single body system. Serious drug-related AEs and drug-related discontinuations were very rare (median 0.3 and 0.9%, respectively). Limitations included the inability to stratify by age group, particularly neonates. Conclusions and Relevance Overall, AEs in paediatric antibiotic CTs were predictable and class-specific, and no unexpected (age-specific) side effects were identified. Smaller, open-label, dose-finding, high-quality, single-arm pharmacokinetic trials seem potentially sufficient for Electronic supplementary material The online version of this article (https://doi.org/10.1007/s40265-017-0850-x) contains supplementary material, which is available to authorized users.
Introduction
Drug development for children remains challenging, with nearly half of paediatric medicines in Europe prescribed off-label [1, 2] . The introduction of new antibiotics to routine paediatric care is a particularly urgent issue due to the global challenge of antimicrobial resistance. The barriers to conducting clinical trials (CTs) of antibiotics in children have been previously reported [3] , and several initiatives have been put in place to bridge this gap to improve the efficiency and feasibility of paediatric CTs [4] [5] [6] .
Recruiting children into antibiotic CTs is challenging and trials need to be made as efficient as possible. The European Medicines Agency (EMA) and the US FDA encourage modelling and simulation for dose finding and to extrapolate data on efficacy from adult studies [7, 8] . Although the concept of extrapolation of efficacy endpoints in paediatric trials is well-established, the extrapolation of safety has not been accepted generally by regulators. The overall aim is to improve the efficiency of trials in children and maximise the amount of information extracted from adults, without compromising the quality of evidence for regulatory decisions [8] . However, age stratification showed that some safety signals may be detected only in specific age groups [9] . Therefore, the collection of safety data to identify unexpected (age-specific) adverse events (AEs) may be required in the target population when a drug use is age-specific or an age-specific risk is expected [10] . On the other hand, the reporting of pharmacovigilance data on antibiotics in neonates and children is currently limited. Pharmaceutical companies conduct a comprehensive assessment of drug safety following marketing approval and then submit this data to the drug regulatory authority; however, this process requires a significant amount of resources, with the result that AEs are often underreported, especially in cases of uncomplicated non-serious events [11] .
The overall aim of this systematic review was to provide a summary overview on the appropriateness of safety data reported in CTs of antibacterial agents in children and neonates. The specific objectives were (1) to evaluate the overall quality of safety trials conducted in children and (2) to determine if age-specific AEs could be identified for different antibiotic classes.
Methods
The Medline (Ovid MEDLINEÒ without Revisions 1996) and Cochrane CENTRAL (Issue 6 of 12, June 2016) databases were systematically searched on 2 June 2016, using a strategy combining Medical Subject Heading (MeSH) and free-text terms that included 'antibiotic' AND 'randomized controlled trial' AND 'safety' in children (0-18 years). The search was limited to CTs published after 2000. The ClinicalTrials.gov register was also systematically searched on 2 June 2016 for registered CTs using the same strategy. The search was limited to ongoing trials and trials closed in the last 5 years (2011-2016) in order to cover the publication gap. No language restriction was applied. The full strategy is available in the Online Resource.
All trials in which safety was declared as a primary or secondary endpoint were included. Exclusion criteria were (1) topical or inhalational route of administration, (2) noninfectious conditions, (3) administration for prophylaxis rather than treatment, (4) selected population (i.e. cystic fibrosis, malignancies, immunodeficiencies, HIV and tuberculosis), and (5) study design different from randomized controlled trials (RCTs). Trials reporting data on both adults and children were included only if paediatric results were reported separately.
Two authors (PP and LF) independently reviewed and extracted the data, and disagreements were resolved by discussion with a third author (JB). Data on trial design, population, inclusion and exclusion criteria, primary and secondary endpoints, intervention, safety parameters (clinical, laboratory or hearing test), and timing of safety assessment were extracted. For each randomized arm, the number of overall and body-system-specific AEs (classified according to DAIDS [Division of AIDS] recommendations [12] ), treatment discontinuations due to AEs, and mortality, were also collected. We collected serious AEs (SAEs) [13] and serious drug-related AEs (SDR-AEs) as defined by the authors. Laboratory-related AEs were included if assessed as a measure of safety evaluation in the trial design or if defined as pathological by the investigators.
To assess the quality of published trials, the Extension for harms for Consolidated Standards of Reporting Trials (CONSORT) Statement 2004 was used [14] . The proportion of CONSORT items adequately reported was calculated for each CT.
This review complies with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [15] .
Statistical Analysis
Proportions have been calculated based on the total number of trials or patients reported as the safety population. Overall and body-system-specific AEs were calculated per single drug class as median and interquartile range (IQR) of the proportions across CTs. AEs reported in less than three CTs in single drug classes were summarised by means. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) for overall and body-system-specific AEs were calculated. To determine statistical differences between groups the Chi-square test was used.
The two-tailed Mann-Whitney U test for two independent samples was used to compare the CONSORT score among CTs having safety as a primary versus secondary endpoint, published before or after the publication of the CONSORT statement (2000-2004 vs. 2005-2016) , and to compare the proportions of reported AEs between nonprofit and industry-funded trials. A p value\0.05 was considered statistically significant. Statistical analyses were carried out using STATA version 14.0 (StataCorp LLC, College Station, TX, USA).
The meta-analysis included CTs investigating those drug classes that were most represented in our sample (i.e. involving the great majority of children) and whose arms had different antibiotics to be compared. Among these CTs, we compared the AEs that were most frequently reported. The meta-analyses were performed using Review Manager (RevMan) version 5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). We used a random-effects model because of the high potential heterogeneity across trials (different conditions, different comparators), which was assessed using the I 2 measure of inconsistency. Publication bias was assessed using funnel plots.
Results

Trial Selection and Description
Our search generated a total of 4044 records, of which 1157 were registered trials. Overall, 290 papers were assessed on full-text, 207 (71.4%) of which were excluded, as shown in Fig. 1 . The main reasons for exclusion were trials conducted only in adults or conducted in adults and children, with safety assessment not reported by age group, non-randomized design, topic different from safety, administration for prophylaxis purpose, and excluded languages (Chinese, Japanese, Russian, Serbian). Overall, 83 RCTs were included in the final analysis, with 62 published trials and 21 trials registered in ClinicalTrials.gov. All the included trials accounted for 29,134 children. Trial characteristics are reported in Electronic Supplementary Table 1 . Due to the lack of available results, the 21 trials registered in ClinicalTrials.gov were only analysed in a descriptive way and for quantitative information on trial design (e.g. sample size per investigated drug class). Different levels of performed analyses are show in Fig. 2 . Seventeen (21%) of the included trials assessed safety as a primary endpoint [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] , 64 (77%) as a secondary endpoint , and two (2%) as both primary and secondary endpoints [97, 98] . Two trials were placebo-controlled [92, 94] (Table 1) . Five CTs (6%) did not restrict the study population to paediatric age but also included adult patients [47, 48, 67, 70, 83] . Overall, 1441/29,134 children (4.9%) were not included in the quantitative analyses because it was not possible to define the administered drug (i.e. only defined as standard of care, or different comparator per different age group). Furthermore, 27,693/29,134 children were included and stratified by drug class according to the assigned treatment (Electronic Supplementary Table 2) . Penicillins were the most frequently studied drug class (11,408 children), followed by aminoglycosides and cephalosporins (Electronic Supplementary Table 2) . A single antibiotic was administered to 18,398 children, with a combination of two or more antibiotics used in 9295 children. Among the latter, 77.3% (7186 children) were treated with a combination of penicillin and aminoglycoside.
Quality Assessment
The 62 published RCTs were assessed for quality, according to the number of CONSORT Statement items adequately reported. An overall mean of 69.7% items (range 33.3-100) was reported properly. There was no evidence of difference between trials reporting safety as a primary (77.4%) or secondary (68.2%) endpoint (p = 0.05). The most frequent recommendation that trials did not report on (45/62, 72.6%) was item number three ('List addressed AEs with definition for each'), which should be reported in the Methods section. Only 20 (32%) of 62 trials clearly defined their safety parameters in the publication, providing details about expected versus unexpected AEs, mode of data collection (spontaneously reported or assessed by investigator), pathologic values defining toxicity (e.g. 'nephrotoxicity was defined as doubling in serum creatinine concentration compared with baseline'), grading and timing of evaluation of each AE [19-23, 33-36, 42, 46, 54, 55, 60, 62-66, 80] . Just six trials provided a reference for the definitions of AEs (two DAIDS [63, 82] , two Coding Symbols for a Thesaurus of Adverse Reaction Terms (COSTART) [66, 84] , and two World Health Organization (WHO) coding systems [35, 53] ). The justification for sample size and definition of safety population were only provided by two of the ten published trials including safety as a primary endpoint [24, 98] .
Quantitative Analysis of Reported Adverse Events (AEs)
Published RCTs in which the number of body-systemspecific AEs was recorded were included in the quantitative analysis ( [99] . The median proportion of children with reported AEs across the trials was 22.5% (IQR 7.7-44.6), while the median rate of discontinuation of therapy due to AEs was\1% (0.9%, IQR 0-3). There was no evidence of difference in the proportion of reported AEs between trials funded by industry and non-profit CTs (p = 0.05).
Clinical AEs
Systemic AEs, including fever, allergic reactions and Red Man Syndrome, were most frequently reported in children receiving glycopeptides (glycopeptides vs. others: OR 14.3, 95% CI 10.0-20.2; p\0.0001). Among these AEs, 40/48 (83%) were clearly class-specific (e.g. Red Man Syndrome) [100] . Anaphylaxis was only reported in children taking amoxicillin (3/1261, 0.002%).
Ten trials reported mortality during the study period, with a rate of 66/15,716 children (0.4%), none of which was attributed to the intervention drug by the investigator [16, 20, 24, 35, 44, 45, 53, 55, 63, 84] .
Nineteen trials reported SAEs separately from AEs, in 1.8% of children (137/7760) [20, 24, 35-37, 44, 45, 53, 59, 60, 65, 68, 69, 71, 74, 79, 82-84] . Among these trials, eight trials further specified how many SAEs were 81 children experienced severe diarrhoea, 1%) . None of the trials conducted on macrolides investigated or reported cardiotoxicity.
Nearly half of the reported AEs (2254/5189) involved the gastrointestinal (GI) system (7.7%, IQR 0.0-20.5). Among these AEs, diarrhoea and vomiting accounted for 49.0 and 22.3%, respectively (1104 and 502 of 2254 children, respectively). Children receiving amoxicillin had a significantly higher risk of developing antibiotic-associated diarrhoea than children receiving macrolides (OR 2.3, 95% CI 1.6-3.1; p\0.0001), a lower but not statistically significant risk compared with cephalosporins (OR 0.8, 95% CI 0.6-1.0; p = 0.06), and significantly lower risk compared with penicillin ? BLIs (OR 0.3, 95% CI 0.3-0.4; p\0.0001). Two studies further specified how many diarrhoea AEs were diagnosed as Clostridium difficile-associated diarrhoea [24, 56] . Specifically, only one child of 13 (7.7%) treated with a low-dose course of cefuroxime axetil experienced Clostridium difficile-associated diarrhoea after completing the treatment [56] .
Among neurological AEs, 42 of 47 (89%) were reported as headache, and 5 of 47 (11%) were reported as convulsions. The latter were all reported in the same trial and were classified by authors as SAEs [60] . Musculoskeletal AEs were only reported for fluoroquinolones (56/78, 72%) and penicillins ? BLIs (22/78, 28%). Among these musculoskeletal AEs, 39/78 (50%) were arthralgia and 28/78 (36%) were myalgia.
Laboratory AEs
Laboratory AEs, including biochemical and haematological parameters, were evaluated in 15 trials [20, 24, 42, 44, 45, 60, 63, 70-72, 76, 82-84, 98] . The highest proportions were reported in children receiving linezolid (linezolid vs. others: OR 8.1, 95% CI 6.5-10.0; p\0.0001) and glycopeptides (glycopeptides vs. others: OR 5.6, 95% CI 4.2-7.5; p\0.0001). For both classes, most laboratory AEs were haematological (linezolid 169/215 [78.6%], glycopeptides 63/84 [75%]). Comparing these two antibiotics, the risk of developing laboratory AEs was not statistically different (p = 0.948); however, the risk of overall AEs was higher with glycopeptides than linezolid (OR 1.9. 95% CI 1.4-2.6; p = 0.0001).
Meta-Analysis
Twenty-six RCTs (7305 children) were included in the meta-analysis. The most frequently reported AEs were compared through forest plots. The risk of antibiotic-associated diarrhoea was significantly higher with penicillins ? BLIs [risk ratio (RR) 2.4, 95% CI 1.8-3.2] and lower in cephalosporins (RR 0.6, 95% CI 0.4-1.0) Upper respiratory tract infections included otitis media, while gastrointestinal infections included complicated intra-abdominal infections compared with other b-lactams. There was no evidence of differences between penicillins and other b-lactams (RR 1.1, 95% CI 0.9-1.2) (Fig. 3) .
The meta-analyses of nephrotoxicity and ototoxicity in aminoglycosides did not find any evidence of differences between one daily dose (OD) and multiple doses (MD) (nephrotoxicity: RR 0.8, 95% CI 0.4-1.6; ototoxicity: RR 1.5, 95% CI 0.3-6.6) (Electronic Supplementary Fig. 1 ). Overall, there was no evidence of differences in the proportions of reported AEs with macrolides versus penicillins (RR 0.9, 95% CI 0.8-1.2) (Electronic Supplementary  Fig. 2) ; however, there was some suggestion of publication bias based on funnel plots (Electronic Supplementary  Fig. 3 ). 
Discussion
This systematic review included 83 paediatric RCTs on the safety of antibiotics, with the majority of the trials conducted on three antibiotic drug classes (b-lactams, macrolides, aminoglycosides). Although 21 of the selected CTs included neonates, only three were specifically designed to study the neonatal population. The quality of reporting AEs was suboptimal in the great majority of CTs due to the frequent lack of a detailed definition of both expected and unexpected AEs. Although 10/62 published CTs were designed with safety as the primary endpoint, only two trials provided the justification for the sample size specifically for the safety population. Overall, data reported for those drug classes most commonly used in children demonstrated clearly that AEs in the paediatric antibiotic CTs were both class-specific and predictable. Within the limitations of the lack of neonatal data, we did not identify age-specific or unexpected toxicity, with virtually all AEs graded as non-severe. Discontinuation of treatment due to AEs, including both drug-related and unrelated, was notably low. Moreover, only 1 of the 83 CTs investigated a new antibiotic (solithromycin), which is included in the Pew Charitable Trusts list [60, 101] . This study represents the first systematic review of the key components of safety in paediatric antibiotic CTs across all clinical infectious syndromes. The aim was to provide a summary overview on both the qualitative and quantitative reporting of AEs. We could identify no similar data available for the adult population since most reviews on safety in adults have been conducted on patients with specific infectious diseases, or on specific antibiotic classes [102] [103] [104] . A study conducted on antiretroviral drugs comparing safety between adults and children, based on data provided by the FDA, showed that adult AEs can preliminary inform the safety profile in children, even if Fig. 3 Diarrhoea in b-lactams: meta-analysis. M-H Mantel-Haenszel, CI confidence interval, df degrees of freedom specific types and rates in paediatrics cannot exclusively be extrapolated from adults [105] .
Similar to our study, papers targeting the safety of specific drugs in children demonstrated that most of the AEs were classified as non-serious and were generally scarcely reported [106] [107] [108] [109] . The poor quality of safety reporting has also been noted in other studies investigating non-infectious conditions in children (e.g. epilepsy) or, collectively, all paediatric drugs [109, 110] . In a review evaluating the quality of reporting adverse drug reactions in RCTs performed in children over a 4-year period, only 19 of 83 CTs had a CONSORT score considered as sufficient by the authors (C 6, range 1-10) [110] . Although our CONSORT assessment noted that 45/83 trials had C 60% of items adequately reported, this is relatively low considering that we selected only CTs having safety as the primary or secondary endpoints. Conversely to one previous study, our overall AE rates did not differ between nonprofit and industry-funded CTs [110] . Together, these findings suggest that more emphasis should be placed on the complete reporting of AE methods and definitions in Supplementary Material, particularly when trial protocols are not available online.
Several initiatives in both the US and EU aim to improve and facilitate the enrolment of children in antibiotic CTs [4, 5] . Paediatric antibiotic safety trials have traditionally included a standard-of-care comparator arm. Variation in the choice of comparator agent internationally, and the subsequent complexity of trial design and conduct, has led to a high burden on limited paediatric research staff with consequent recruitment difficulties. Other initiatives, such as the Pediatric Health Information System (PHIS) in the US, have currently been put in place to improve the reporting of pharmacovigilance data on antibiotics in neonates and children following marketing approval [111] ; however, these large databases have high costs and require high-level electronic infrastructures to collect the data throughout different centres. A different approach could be the establishment of a network of different stakeholders (academics, physicians, regulators and governments) who share common interests in paediatric pharmacovigilance. The Global Alignment of Immunization Safety Assessment in Pregnancy (GAIA) project represents a good example of how a voluntary network can improve the quality of safety data in a specific population [112] . In an attempt to gather more evidence on efficacy and safety data for antimicrobial drugs in children, some web-based, disease-specific drug registries have been put in place in Europe in the last decades to enhance the exchange of information and expertise between centres [113, 114] . Among other information, these registries prospectively collect toxicity data in children, are generally open access and are relatively cheap to maintain.
One of the main limitations of this review is the high heterogeneity in terms of trial design, population, and data reporting that might reduce the strength of our conclusions. The evaluation of overall, instead of drug-related, AEs was due to the limited number of trials clearly defining the attribution method to assess the causality between the studied drug and the AE (such as including AEs secondary to the infectious condition rather than the drug itself, possibly leading to an overestimation). Another limitation is that other possible determinants, such as route of administration and dose, have not been taken into account because of the lack of specific information provided by the investigators. The exclusion criteria applied in the search limit the conclusions of this review to children with an acute infectious disease but otherwise apparently healthy. Immunocompromised children may require longer courses of treatment and/or higher doses of treatment and therefore safety may differ. Rare AEs were essentially not reported, raising concerns about reporting bias and limitations of sample size, considering that most of the included studies were unpowered to detect infrequent AEs. Lastly, it was not possible to stratify safety data by different paediatric age groups because AEs were not reported separately by the authors. Because of the lack of historical data published before the year 2000, AEs previously recognised in the literature as specific to children were not detected in this systematic review (e.g. no chloramphenicol-related grey baby syndrome was reported, and only one trial on amphenicols including 25 children aged\8 years was included) [115] .
The implications of this review are that for certain common antibiotic classes, with well-established safety profiles (e.g. b-lactams, macrolides) determined from large adult efficacy trials, it may be possible to simplify the safety assessments in parallel paediatric trials when drug exposure is similar in children and adults. Smaller, openlabel, dose-finding, high-quality, single-arm pharmacokinetic trials collecting safety data to confirm no unanticipated child-specific toxicities may be more feasible, enhance recruitment and subsequent registration of needed new drugs. It has usually been considered that extrapolation of safety from adults to children was not possible due to the growth and development characteristics of children, and due to the impact that organ maturation has throughout the different stages of childhood (particularly applicable to neonates and young children). Antibacterial agents usually target components of the bacterial cell or selected cellular processes essential for the survival of pathogenic bacteria rather than interacting with human targets. Therefore, extrapolation of safety may be considered as a potential approach to decrease the burden on paediatric patients, i.e. to take advantage of the prior knowledge in adult trials that can be used to streamline the paediatric clinical development. Most of the agreed (between the Paediatric Committee at EMA and applicants) Paediatric Investigation Plans (PIPs) include, as part of the clinical development, pharmacokinetic studies across all age subsets of the paediatric population (unless safety issues preclude the use in some age groups, e.g. the case of the tetracycline class of antibiotics and children under 8 years of age), followed by a safety and efficacy study that is usually a randomised, active comparator study in a substantial number of children evenly distributed across the different age groups. This has resulted in the delayed (of approximately 5-7 years) availability of antibacterial agents for the paediatric population when compared with their availability (i.e. regulatory approval) for adult subjects. Once the antibacterial agent is in the market, nothing prevents its off-label use, which also makes the conduct of randomised trials difficult. There is therefore a clear need to speed up the paediatric clinical development. The challenge is to identify under which circumstances the conduct of smaller, open-label, dose-finding, high-quality, single-arm pharmacokinetic trials may not be sufficient for regulatory purposes (approval). In this respect, it has been discussed that toxicity data in juvenile animals can inform this decision. Safety concerns that have limited the use of certain antibacterial agents in the paediatric population have been primarily identified in animal studies, such as the case of quinoloneinduced articular toxicity, or the permanent dental defects and the delay in ossification processes in fetuses occurring with tetracyclines. A safety study may be unavoidable in the presence of off-target effects identified in the nonclinical setting that are shown (e.g. in adult subjects) to have clinical relevance, particularly for the paediatric population as a whole or for some age subsets. This can be the case for antibiotics such as fluoroquinolones, linezolid or daptomycin, or for antibacterial agents with new mechanisms of action. Safety studies usually require very large sample sizes and it is questionable whether this can be achieved in the frame of standard CTs, particularly when the number of subjects is limited, as is the case for the paediatric population. On the other hand, the proposal of a simplified strategy will need to be combined with enhanced methods of pharmacovigilance for monitoring of emerging AEs in routine clinical practice. The institution of a European electronic registry using the well-established PENTA network (http://www.pentatrials.org) would be a potential option to collect safety and outcome data on both new and old off-patent key antibiotics in children and neonates, including all those antibacterials currently used off-label. The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) is an international network of cohort studies coordinated by PENTA, conducting epidemiological research on HIV-infected pregnant women, children and children exposed to HIV in utero, with a programme of work including individual patient data metaanalyses, pharmacovigilance projects and other observational studies. Of note, in September 2015 the EMA launched an initiative that explores ways of expanding the use of patient registries by introducing and supporting a more systematic and standardised approach to their contribution to the benefit-risk evaluation of medicines within the European Economic Area [116] . Such an approach could potentially allow data to be collected and easily pooled out at a relatively low cost, and help gather evidence to improve the design and conduct of paediatric CTs. Given the highly concerning rates of antimicrobial resistance that are a rapidly emerging threat to global child health, optimal trial designs to most efficiently bring both new and older re-entry antibiotics into routine clinical care are urgently required.
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